Tarceva

Type: Product
Name: Tarceva
First reported Oct 22 2014 - Updated Oct 22 2014 - 1 reports

For Patients With Advanced Non-Small Cell Lung Cancer (NSCLC), Dacomitinib Not Superior to Erlotinib

the Cancer Therapy Advisor take:According to a new study published in the journal The Lancet Oncology , researchers have found that dacomitinib was not superior to erlotinib in patients with advanced non-small cell lung cancer (NSCLC) or in patients with ... [Published Chemotherapy Advisor - Oct 22 2014]
First reported Oct 21 2014 - Updated Oct 21 2014 - 2 reports

Emerging Markets Earnings Roundup: Roche (Part 2)

Roche feels the heat still from Tarceva competition in China, but Japan regains luster as sales tax hit dims and diagnostics benefit as governments in emerging markets ramp up health care spending. ... [Published Health News Daily - Oct 21 2014]
First reported Oct 19 2014 - Updated Oct 19 2014 - 1 reports

New Treatment Strategies Emerge for Non-Small Cell Lung Cancer

Philippe Bishop, MDThe treatment of patients with non-small cell lung cancer (NSCLC) who harbor an actionable mutation in EGFR or ALK continues evolve, as clinical trials begin exploring next-generation agents and combination strategies.Two studies recently ... [Published OncLive - Oct 19 2014]
First reported Oct 19 2014 - Updated Oct 19 2014 - 1 reports

NCI Launches ALCHEMIST Precision Medicine Trials for Patients with Certain Types of Early Lung Cancer

Image ToolsThe National Cancer Institute has launched a series of trials called ALCHEMIST, designed to identify early-stage lung cancer patients with tumors that harbor certain uncommon genetic changes and evaluate whether drug treatments targeted against ... [Published Oncology Times - Oct 19 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Epidermal Growth Factor Inhibition, a Novel Pathway to Prevent Chronic Allograft Injury

BackgroundChronic allograft injury remains a major problem in clinical kidney transplantation and different growth factors participate in its development. Epidermal growth factor (EGF) affects cell proliferation and mitogenesis through its tyrosine kinase ... [Published Transplantation - Oct 16 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Roche Holding's (RHHBY) CEO Severin Schwan on Q3 2014 Results - Earnings Call Transcript

Roche Holding Ltd ADR ( OTCQX:RHHBY ) Q3 2014 Earnings Conference Call October 16, 2014 8:00 AM ETOperatorLadies and gentlemen, good morning and good afternoon. Welcome to the Roche Third Quarter Results 2014 Conference Call. I'm Stephanie, the Chorus ... [Published Seeking Alpha - Oct 16 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Roche posts solid sales performance for first nine months of 2014

Swiss pharma major Roche (ROG: SIX) this morning released its financials for the first nine months of 2014, showing that group sales were 34.8 billion Swiss francs ($36.98 billion), 5% higher at constant exchange rates and stable in Swiss francs.In the ... [Published Pharma Letter - Oct 16 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Comment PanHER inhibition in EGFR wildtype nonsmallcell lung cancer

Since 2005, erlotinib has been indicated for unselected patients with non-small-cell lung cancer as second-line or third-line treatment, after findings from the BR.21 trial showed that erlotinib could increase overall survival by 2 months, irrespecti ... [Published BioPortfolio - Oct 16 2014]
First reported Oct 02 2014 - Updated Oct 02 2014 - 2 reports

New trial results for advanced squamous cell carcinoma of the lung

News, Oct 2 2014.Phase III data from the LUX-Lung 8 trial, the first study to directly compare the efficacy of afatinib versus erlotinib patients with advanced squamous cell carcinoma (SCC) of the lung, demonstrated superior progression-free survival ... [Published GM Journal - Oct 02 2014]
First reported Sep 27 2014 - Updated Sep 28 2014 - 2 reports

SAPA - PR-LUX-LUNG-8-TRIAL

PR-LUX-LUNG-8-TRIALContributed by NAMPA / SAPA.SAPA PR -- LUX-LUNG 8 TRIAL MET IS PRIMARY ENDPOINTIssued by: Business WireAttention: Health EditorsFor immediate release:Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib ... [Published Namibia Press Agency - Sep 27 2014]
First reported Sep 26 2014 - Updated Sep 27 2014 - 2 reports

Strategy to reduce side effects in modern cancer therapy -- ScienceDaily

The occurrence of severe side effects and the development of resistance are two of the biggest problems facing modern cancer therapy. Even the latest, highly targeted cancer drugs such as the tyrosine kinase inhibitors Tarceva(R) or Sutent(R) are affected ... [Published DailyMe.Com - Sep 27 2014]
Entities: Cancer, Strategy, Sutent, Tarceva
First reported Sep 23 2014 - Updated Sep 24 2014 - 2 reports

Antacids linked to reduced erlotinib efficacy

medwireNews: Acid suppression (AS) therapy may negatively impact outcome among patients receiving erlotinib for advanced non-small-cell lung cancer (NSCLC), Canadian study findings show.The researchers therefore advise “caution” to oncologists prescribing ... [Published MedWire News - Sep 24 2014]

Quotes

...tested and when and how the testing is implemented," said Natasha Rekhtman, MD, PhD, co-chair of ASCO's Expert Panel that endorsed the guideline. "We hope that it will encourage testing and treatment based on molecular results."
"The guideline recommends that small tumor samples of other histologies, for which an adenocarcinoma component cannot be excluded because of sampling, can be considered for testing, particularly if clinical criteria are suggestive (eg, younger age, lack of smoking history)" write the ASCO authors
"Described herein are methods of assessing status of a subject with distant metastasis NSCLC, comprising: detecting presence or absence of one or more mutated EGFR nucleic acid sequence in blood from the subject with distant metastasis stage NSCLC; and assessing the status of the subject with distant metastasis stage NSCLC based on the detected presence or absence of the one or more mutated EGFR nucleic acid sequence. Also described herein are methods of assessing status of a subject with NSCLC, comprising: detecting presence or absence of one or more mutated EGFR nucleic acid sequence in a blood of the subject; and assessing the status of the subject based on the detected presence or absence of the one or more mutated EGFR sequence. Also described herein are method of identifying a candidate NSCLC patient for a targeted drug therapy, comprising: detecting presence or absence of one or more mutated EGFR sequence in blood from the patient; assessing metastatic status of the NSCLC patient as M1a or M1b; and identifying the patient as a candidate for the targeted drug therapy based on at least the detected presence of the one or more mutated EGFR sequence in the blood of the patient, and the metastatic status of NSCLC in the patient. Also disclosed herein are methods of assessing status of a subject with a solid tumor cancer, comprising: detecting presence or absence of one or more tumor-associated mutated nucleic acid sequence in blood from the subject with the solid tumor cancer; and assessing the status of the subject with distant metastasis solid tumor cancer based on the detected presence or absence of the one or more mutated tumor-associated nucleic acid sequence. Furthermore, disclosed herein are methods of detecting presence or absence of a tumor-associated mutation in a blood sample, the methods comprising: performing a quantitative real-time polymerase chain reaction (PCR) on the blood sample using primers specific for a mutated nucleic sequence to generate a PCR cycle threshold; and comparing the cycle threshold to a control value, wherein the control value takes into account the concentration of genomic DNA in the sample, and wherein if the cycle threshold is below the control value the tumor-associated mutation is present in the sample and if the cycle threshold is above the control value the tumor-associated mutation is absent from the sample. Methods of treating patients or subjects with solid tumor cancers, such as NSCLC, are also envisioned and included within the scope of the methods described herein. Variations and combinations of the above methods and their various steps and substeps are also envisioned and included within the scope of the described methods."
methodologies, and streamlining the reimbursement process of biomarker -- "Payers also look favorably on biomarker-driven prescribing, and this can"

More Content

All (141) | News (129) | Reports (0) | Blogs (10) | Audio/Video (0) | Fact Sheets (2) | Press Releases (0)
sort by: Date | Relevance
A conversation with a cancer patient about pall... [Published Health Canal - 8 hours ago]
Afatinib active against NSCLC nervous system me... [Published MedWire News - Oct 22 2014]
For Patients With Advanced Non-Small Cell Lung ... [Published Chemotherapy Advisor - Oct 22 2014]
Highmark Insurance Company Announces Coverage f... [Published Clinical Lab Products - Oct 21 2014]
Emerging Markets Earnings Roundup: Roche (Part 2) [Published Health News Daily - Oct 21 2014]
Emerging Markets Earnings Roundup: Roche (Part 2) [Published BioPortfolio - Oct 21 2014]
ASCO Endorses Lung Cancer Guidelines for Molecu... [Published Cancernetwork.com - Oct 20 2014]
Green Tea and Fighting Cancer [Published Examiner.com - Oct 20 2014]
New Treatment Strategies Emerge for Non-Small C... [Published OncLive - Oct 19 2014]
NCI Launches ALCHEMIST Precision Medicine Trial... [Published Oncology Times - Oct 19 2014]
Epidermal Growth Factor Inhibition, a Novel Pat... [Published Transplantation - Oct 16 2014]
Roche Holding's (RHHBY) CEO Severin Schwan on Q... [Published Seeking Alpha - Oct 16 2014]
Roche posts solid sales performance for first n... [Published Pharma Letter - Oct 16 2014]
Comment PanHER inhibition in EGFR wildtype nons... [Published BioPortfolio - Oct 16 2014]
Novel Approach of MALDI Drug Imaging, Immunohis... [Published Analytical Chemistry - Oct 16 2014]
Managing Resistance to Targeted Agents: The Fut... [Published The ASCO Post - Oct 15 2014]
Tarceva Forecast [Published PR Newswire: Entertainment & Media - Oct 14 2014]
ASCO Endorses CAP/IASLC/AMP Guideline on EGFR a... [Published American Society of Clinical Oncology - Oct 13 2014]
ASCO Endorses Guideline on EGFR and ALK Testing... [Published Oncology Times - Oct 13 2014]
ASCO: Molecular Testing for All Lung Adenocarci... [Published American Journal of Public Health - Oct 13 2014]
Forum Post: RE: Treatment Plan [Published Macmillan Cancer Support - Oct 13 2014]
Forum Post: RE: living in 3 months sections [Published Macmillan Cancer Support - Oct 13 2014]
Tarceva Forecast: New research released [Published Live-PR.com - Oct 10 2014]
Atypical response to erlotinib in a patient wit... [Published 7thSpace - Oct 09 2014]
Researchers Submit Patent Application, "EGFR Bl... [Published 4 Traders - Oct 08 2014]
Forum Post: ERLOTINIB (TARCEVA) - TREATMENT IN ... [Published Macmillan Cancer Support - Oct 07 2014]
Humanized AXL antibodies [Published PharmCast - Oct 07 2014]
ARIAD Gets Breakthrough Therapy Designation for... [Published Zacks.com - Oct 06 2014]
A Bayesian Meta-Analysis of Multiple Treatment ... [Published Plosone.org - Oct 06 2014]
Use 'TKI as Long as You Can' in NSCLC [Published American Journal of Public Health - Oct 06 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Tarceva Forecast [Published PR Newswire: Entertainment & Media - Oct 14 2014]
LONDON, Oct. 14, 2014 /PRNewswire/ -- The BCC Research Tarceva Forecast is a quantitative forecast model in an easily accessible Microsoft Excel spreadsheet, segmented by specific parameters.The introductory sample of the Tarceva Forecast Model was ...
Head-to-head Phase III trial demonstrates super... [Published PR Newswire: Health - Sep 29 2014]
RIDGEFIELD, Conn., Sept. 29, 2014 /PRNewswire/ -- Phase III data from Boehringer Ingelheim's LUX-Lung 8 trial, the first study to evaluate the superiority of afatinib versus erlotinib in patients with advanced squamous cell carcinoma (SCC) of the lung, ...
Head-to-head Phase III trial demonstrates super... [Published Business Wire Health News - Sep 27 2014]
INGELHEIM, Germany--(BUSINESS WIRE)--For Ex-US and Ex-UK Media Only Phase III data from Boehringer Ingelheim’s LUX-Lung 8 trial, the first study to directly compare the efficacy of two different targeted agents in patients with advanced squamous cell ...
Advancing medicine, layer by layer [Published MIT News feed - Jul 01 2014]
Personalized cancer treatments and better bone implants could grow from techniques demonstrated by graduate students Stephen W. Morton and Nisarg J. Shah, who are both working in chemical engineering professor Paula Hammond's lab at MIT. Morton's work ...
Tarceva Forecast [Published PR Newswire: Entertainment & Media - Jun 19 2014]
NEW YORK, June 19, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Tarceva Forecasthttp://www.reportlinker.com/p02162048/Tarceva-Forecast.htmlThe BCC Research Tarceva Forecast is a quantitative ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.